The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review

Uraz, Süleyman; Deniz, Zeynep; Zerdali, Esra; Araslanova, Adel; Tahan, Veysel; Tabak, Fehmı; Özaras, Reşat

doi:10.1111/jvh.13834

Cited by 3 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent systematic study was published by Uraz et al [19] ; using a very simple methodology, the authors calculated a mean, adding each prevalence from various studies, of which some studies included very few subjects. With this debatable methodology, Uraz et al [19] reported that after 2010, the anti-HDV prevalence was 5.5% for all patients with HBV infection without cirrhosis (with an HDV prevalence estimate of 5.2% in inactive HBsAg carriers and of 6.9% in patients with CHB). Their estimate falls above the high range of our 95% CI (4.00-6.23) for all HBsAg-positive patients without cirrhosis (outpatient studies).…”

Section: Discussionmentioning

confidence: 99%

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Toy,

Güler,

Somay

et al. 2024

IJID Regions

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Toy,

Güler,

Somay

et al. 2024

IJID Regions

View full text Add to dashboard Cite

“…Global prevalence of HDV was higher in 1977-1996 than in 1997-2016, however, an opposite trend was observed in some countries, like Japan and Gabon [134]. A study from Turkey demonstrated an overall decrease in HDV prevalence from 8.3% observed in years before 1999 to 5.5% after 2010 [122]. In Italy, the decline in incidence of acute hepatitis D occurred in parallel with the decrease in incidence of acute hepatitis B, suggesting an effect of hepatitis B vaccination on both infections [123].…”

Section: Reduction In Hepatitis D Virus Infectionsmentioning

confidence: 99%

Hepatitis B Vaccine: Four Decades on

Mironova,

Ghany

2024

Vaccines

View full text Add to dashboard Cite

Hepatitis B virus is a substantial contributor to cirrhosis and hepatocellular carcinoma (HCC) globally. Vaccination is the most effective method for prevention of hepatitis B and its associated morbidity and mortality, and the only method to prevent infection with hepatitis D virus. The hepatitis B vaccine has been used worldwide for more than four decades; it is available in a single- or triple-antigen form and in combination with vaccines against other infections. Introduction of the vaccine and administration at birth led to sustained decline in mother-to-child transmission, chronic hepatitis B, and HCC, however, global birth dose coverage remains suboptimal. In this review we will discuss different hepatitis B vaccine formulations and schedules, vaccination guidelines, durability of the response, and vaccine escape mutants, as well as the clinical and economic benefits of vaccination.

show abstract

Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?

Demirel,

Uraz,

Deniz

et al. 2023

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Co‐infection with hepatitis delta virus (HDV) is a challenging health care problem worldwide, estimated to occur in approximately 5%–10% of patients with chronic hepatitis B virus (HBV) infection. While HBV prevalence is decreasing globally, the prevalence of HDV infection is rising in some parts mainly due to injection drug use, sexual transmission and immigration from high endemicity areas. Eastern Europe and the Mediterranean are among the regions with high rates of endemicity for HDV and the immigration from high endemicity areas to Central and Western Europe has changed the HDV epidemiology. We aimed to review the prevalence of HDV infection in Europe. A paucity of publication appears in many European countries. Prevalence studies from some countries are old dated and some other countries did not report any prevalence studies. The studies are accumulated in few countries. Anti‐HDV prevalence is high in Greenland, Norway, Romania, Sweden and Italy. Belgium, France, Germany, Spain, Switzerland, Turkey and United Kingdom reported decreasing prevalences. Among cirrhotic HBV patients, Germany, Italy and Turkey reported higher rates of HDV. The studies including centres across the Europe reported that HIV‐HBV coinfected individuals have higher prevalence of HDV infection. The immigrants contribute the HDV infection burden in Greece, Italy, and Spain in an increasing rate. Previous studies revealed extremely high rates of HDV infection in Germany, Greece, Italy and Sweden. The studies report a remarkably high prevalence of hepatitis delta among HIV/HBV‐coinfected individuals, individuals who inject drugs, immigrants and severe HBV infected patients across Europe. The HDV infection burden still appears to be significant. In the lack of an effective HDV therapy, prevention strategies and active screening of HBV/HDV appear as the most critical interventions for reducing the burden of liver disease related to HDV infection in Europe.

show abstract

The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review

Cited by 3 publications

References 60 publications

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Hepatitis delta virus infection in Turkey: A meta-analysis of prevalence

Hepatitis B Vaccine: Four Decades on

Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?

Contact Info

Product

Resources

About